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Introduction
Tissue homeostasis is maintained through a balance
between cell proliferation and apoptosis. Both are active
processes that are influenced by a wide variety of regula-
tory stimuli. Each cell is under constant surveillance in
order to maintain the integrity of its genome. When onco-
AI = apoptotic index; FITC = fluorescein isothiocyanate; P/A index = proliferative index/apoptotic index; PI = proliferative index; TUNEL = TdT-medi-
ated dUTP-nick end-labelling.
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Abstract
Background: Disruption of the balance between apoptosis and proliferation is considered to be an
important factor in the development and progression of tumours. In the present study we determined
the in vivo cell kinetics along the spectrum of apparently normal epithelium, hyperplasia, preinvasive
lesions and invasive carcinoma, in breast tissues affected by fibrocystic changes in which preinvasive
and/or invasive lesions developed, as a model of breast carcinogenesis.
Methods:  A total of 32 areas of apparently normal epithelium and 135 ductal proliferative and
neoplastic lesions were studied. More than one epithelial lesion per case were analyzed. The
apoptotic index (AI) and the proliferative index (PI) were expressed as the percentage of TdT-
mediated dUTP-nick end-labelling (TUNEL) and Ki-67-positive cells, respectively. The PI/AI (P/A
index) was calculated for each case.
Results: The AIs and PIs were significantly higher in hyperplasia than in apparently normal epithelium
(P = 0.04 and P = 0.0005, respectively), in atypical hyperplasia than in hyperplasia (P = 0.01 and
P = 0.04, respectively) and in invasive carcinoma than in in situ carcinoma (P < 0.001 and P < 0.001,
respectively). The two indices were similar in atypical hyperplasia and in in situ carcinoma. The P/A
index increased significantly from normal epithelium to hyperplasia (P=0.01) and from preinvasive
lesions to invasive carcinoma (P=0.04) whereas it was decreased (non-significantly) from
hyperplasia to preinvasive lesions. A strong positive correlation between the AIs and the PIs was
found (r = 0.83, P < 0.001).
Conclusion: These findings suggest accelerating cell turnover along the continuum of breast
carcinogenesis. Atypical hyperplasias and in situ carcinomas might be kinetically similar lesions. In the
transition from normal epithelium to hyperplasia and from preinvasive lesions to invasive carcinoma the
net growth of epithelial cells results from a growth imbalance in favour of proliferation. In the transition
from hyperplasia to preinvasive lesions there is an imbalance in favour of apoptosis.
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genic mutations occur, potent mechanisms exist that limit
the expansion of affected cells by suppressing their prolif-
eration or triggering their apoptosis [1–4].
For some time the deregulation of growth that leads to
cancer was explained largely in terms of increased cell
proliferation. However, during the past decade the role of
apoptosis in tumourigenesis has been extensively studied.
Reduced apoptosis may lead to a shift in tissue kinetics
toward the expansion of cell numbers, and to the preser-
vation of genetically aberrant cells, favouring clonal expan-
sion and neoplastic development [2,5]. Investigators are
increasingly describing cancer as a disease that involves
both excessive cell proliferation and inhibition of the cell’s
ability to die.
Data from histological, epidemiological and experimental
studies suggest that breast carcinogenesis is a multistep
process that starts with hyperplasia, progressing through
atypical hyperplasia to in situ and invasive carcinoma. The
time course of these changes is difficult to estimate
because, during this multistep process, unknown factors
may halt progression through the continuum, and the
hyperplastic lesions may regress and never undergo a
malignant transformation [6–10]. There is no general con-
sensus that the multistep model of breast carcinogenesis
is accurate. Different disease progression models have
been proposed and studied [11–14]. De novo breast car-
cinogenesis cannot be ruled out.
The role of cell kinetics in development and progression of
breast carcinoma remains to be elucidated. Allan et al [15]
found higher mitotic and apoptotic activities in breast car-
cinoma than in normal epithelium; they also found and
reduced apoptosis and apoptosis relative to mitosis in
apparently normal epithelium from breasts with fibrocystic
changes and carcinoma, as compared with breasts with
fibroadenomas. In another morphological study [11], two
disease progression models were used: the well differenti-
ated and poorly differentiated models. In that study, it was
found that the progression from well-differentiated preinva-
sive lesions to well-differentiated invasive carcinoma is
accompanied by increased mitotic index, whereas in
poorly differentiated lesions decreased apoptosis appears
also to be important. Harn et al [16] reported a higher
degree of TUNEL index and lower proliferative activity in
intraductal than in invasive ductal carcinomas.
In the present study, we determined the incidence of
apoptosis (detected using the TUNEL method) and cell
proliferation (assessed using the Ki-67 antibody), and the
balance between these cellular events in apparently
normal epithelium, hyperplasia, atypical hyperplasia, and in
situ and invasive carcinomas, as a model of disease pro-
gression. Both AI and PI were evaluated in at least two
ductal lesions per case, because the aim of this study was
to study the in vivo cell turnover in breast tissue with fibro-
cytic changes, in which preinvasive lesions and/or invasive
carcinoma developed.
Materials and methods
Case selection
Formalin-fixed, paraffin-embedded tissue samples from
67 patients (45 obtained from modified radical mastec-
tomies and 22 from lumpectomies) were used. The
patient’s ages ranged from 38–73 years (median age
49 years). Eleven patients were premenopausal, and the
rest were peri- or postmenopausal. None of the patients
was treated before removal of the tumour. Specimens
were selected from the files of the Department of Pathol-
ogy of the University Hospital of Ioannina, Greece. All of
the hematoxylin and eosin-stained slides were reviewed,
independently, by two pathologists. Only samples from
patients in whom more than one lesion was detected
were included in the study. Two to four slides per case
were selected because each lesion was studied in a dif-
ferent area. The corresponding tissue blocks were then
used for in situ end-labelling (TUNEL) to detect apoptosis,
and for Ki-67 immunostaining to detect cell proliferation.
Apoptotic and proliferative activity were evaluated in iden-
tical areas in serial sections.
The criteria of Page and Rogers [17] were used to identify
hyperplasia of usual type and atypical hyperplasia. Invasive
carcinomas were classified according to the criteria of
Bloom and Richardson, as modified by Elson and Ellis
[18], and in situ ductal carcinomas according to the crite-
ria of Holland et al [19].
A total of 32 samples of apparently normal epithelium and
135 epithelial proliferative lesions were studied. The
lesions comprised the following: 43 ductal hyperplasias of
usual type (15 mild, 10 moderate, 18 severe); 17 atypical
ductal hyperplasias; 25 in situ ductal carcinomas (6 low
grade, 8 intermediate, 11 high); and 50 infiltrating ductal
carcinomas (12 grade I, 20 grade II, 18 grade III). In 12
out of 25 in situ carcinomas an invasive component coex-
isted, and in 9 out of 15 atypical hyperplasias an in situ
and/or invasive carcinoma was detected.
TdT-mediated dUTP nick end-labelling assay
The in situ visualization of DNA fragmentation was per-
formed on paraffin tissue sections (4 mm thick) placed on
superfrost slides, using the commercial in situ end-
labelling Apop Tag Peroxidase and Fluroscein Kit (Oncor;
Gaithersburg, MD, USA). After deparaffinization and
dehydration, slides were rinsed in phosphate-buffered
saline (pH 7.2). Tissue sections were then digested by
incubation for 20 min with proteinase K (20 mg/ml;
Oncor) at room temperature, and then were rinsed in dis-
tilled water. The peroxidase activity was blocked by incu-
bation for 5 min in 2% hydrogen peroxide inBreast Cancer Research    Vol 3 No 4 Bai et al
phosphate-buffered saline. After the application of an
equilibration buffer, slides were incubated in working
strength TdT enzymes that contained dUTP-digoxigenin
for 1 h at 37°C. The reaction was stopped by a pre-
warmed (37°C) working strength stop/wash buffer, and
then slides were rinsed in phosphate-buffered saline. The
incorporated nucleotides were identified by adding perox-
idase-conjugated or fluorescein isothiocyanate (FITC)-
conjugated antidigoxigenin antibody. Slides visualized by
antidigoxigenin–peroxidase were incubated with 3,3¢-
diaminobenzidine tetrahydrochloride (Oncor) and coun-
terstained lightly with Harris’ haematoxylin. Slides
visualized by antidigoxigenin-FITC were counterstained
with propidium iodide (2.5 mg/ml; Oncor). Negative
control slides were prepared by omitting the TdT reaction
step. These sections did not show any nonspecific reac-
tion. Apoptosis within the germinal centres of reactive
lymph nodes served as positive controls.
Immunohistochemistry
Immunohistochemical staining for Ki-67 antigen was per-
formed on paraffin sections (4 mm thick) placed on poly-L-
lysine-coated glass slides. Polyclonal rabbit antibody to
human Ki-67 protein was obtained from Dako (A047;
Dako SA, Glostrup, Denmark). This antibody has a reactiv-
ity similar to that seen with the monoclonal antibody anti-
Ki-67 [12]. After deparaffinization and dehydration,
sections were treated twice for 5 min in citrate buffer
(0.01 mol/l, pH 6.0) in a microwave oven at 700 W. The
slides were then cooled to room temperature for 1 h.
Endogenous peroxidase activity was blocked by immers-
ing the sections in 3% hydrogen peroxide in methanol for
30 min. Nonspecific binding of the secondary antibody
was blocked by incubating the slides with normal rabbit
serum (1/50 dilution ) for 1 h. Sections were then incu-
bated with primary rabbit anti-human Ki-67 antibody
(1/100 dilution) for 1 h at room temperature. Biotinylated
goat anti-rabbit secondary antibody was applied for
60 min at room temperature. Bound antibody was visual-
ized with avidin–biotin–peroxidase complex (Dako Duet
Kit; Dako, K0492; 1/200 dilution) for 1 h at room tempera-
ture. The colour was developed by 3,3¢-diaminobenzidine
tetrahydrochloride. Between steps, the slides were rinsed
three times for 10 min in tris-buffered saline (pH 7.6). The
slides were counterstained lightly in Harris’ haematoxylin,
and were then dehydrated and mounted. Positive control
slides were included in all tests, and consisted of paraffin
sections from lymph nodes with follicular hyperplasia.
Negative control slides were prepared by omitting the
primary antibody.
Counting procedure and assessment of apoptotic and
proliferative indices
For the assessment of TUNEL- and Ki-67-positive cells,
light microscopic examination was performed at a magnifi-
cation of ×400 with the use of a counting grid. Because
the rate of apoptosis was low, TUNEL-positive nuclei were
counted in each selected slide and at least 3000–4000
epithelial cells were evaluated. The AI (expressed as a per-
centage) was determined from the percentage of the ratio
of TUNEL-positive cells to the total number of cells
counted. Areas of obvious tissue necrosis were excluded
from counting. The positive nuclei in Ki-67 staining were
counted in at least 3000 epithelial cells. The percentage
of the ratio of Ki-67 positive cells (PI, also expressed as a
percentage) was calculated. All sections were indepen-
dently evaluated by the two first authors, in collaboration
with other members of the staff.
Statistical analysis
For the statistical evaluation of the results, we used Statis-
tica for Windows (97 edition; Microsoft Corporation), run
on an IBM-compatible personal computer. Differences
among the five tissue groups were assessed by
Kruskall–Wallis analysis of variance. Mann–Whitney test
was used to compare AI, PI and P/A index in the breast
lesions. Correlations between the various indices were
identified using Spearman’s rank test. All values are
expressed as medians (range). P < 0.05 was considered
statistically significant.
Results
Apoptotic and proliferative indices
The AI, as assessed using the TUNEL method, was evalu-
ated in all cases. Cells with and without morphological cri-
teria of apoptosis (shrinkage of the cytoplasm,
condensation and fragmentation of the nuclear chromatin –
membrane blebbing) and apoptotic bodies were positive
(Fig. 1a–c). Nonlabelled cells that satisfied morphological
criteria of apoptosis were counted as apoptotic cells.
TUNEL-positive apoptotic cells were easily distinguished
from necrotic cells, because they were isolated. In order to
avoid false-positive results in the detection of apoptotic
cells, the haematoxylin and eosin consecutive stained sec-
tions and TUNEL sections were compared. Reactive lym-
phocytes around ducts or nests of neoplastic cells were
rarely TUNEL positive. Negative controls run in the TUNEL
assay showed no such reactivity. The AIs obtained using
peroxidase- and FITC-conjugated antidigoxigenin antibody
were not significantly different (P = 0.17).
The PI, as assessed using Ki-67 immunostaining, was
evaluated in all cases. Staining intensity varied consider-
ably among nuclei. In in situ and invasive breast carcino-
mas, as well as in lymphoid germinal centres of reactive
lymph nodes (used as positive controls), in which the AIs
and PIs were higher, we observed Ki-67-positive and
negative cells that satisfied morphological criteria of
apoptosis. Both Ki-67-positive and -negative cells were at
different stages of the apoptotic process (Fig. 2a, b).
There were also Ki-67-positive and -negative apoptotic
bodies (Fig. 2c).The AIs and PIs for each tissue group of lesions are sum-
marised in Table 1. It was obvious from the median values
that both AI and PI increased with the progression of epithe-
lial lesions. One-way analysis demonstrated significant differ-
ences among the tissue groups for both indices (P< 0.001).
Comparison of the indices between the tissue group using
Mann–Whitney tests demonstrated that both AIs and PIs
were significantly higher in hyperplasia than in apparently
normal epithelium (P= 0.044 and P= 0.0005, respectively),
in atypical hyperplasia than in hyperplasia (P= 0.010 and
P= 0.048, respectively), and in invasive carcinoma than in in
situ carcinoma (P< 0.001 and P< 0.001, respectively).
There was no statistically significant differences between
atypical hyperplasias and in situ carcinomas for either AIs or
PIs (P= 0.065 and P= 0.057 respectively). Representative
box plots for AIs and PIs in breast tissue are shown in Fig. 3.
Proliferative/apoptotic index
The ratio of PI to AI was calculated for each individual
case. Cases that did not have apoptosis were excluded
from the calculations of P/A index. The A/P indexes for
each tissue group are summarized in Table 2.
Kruskal–Wallis analysis of variance showed significant dif-
ferences among the tissue groups for both indices
(P < 0.001). Comparison of the P/A indexes between
tissue groups by Mann–Whitney tests showed that P/A
index increased significantly from apparently normal epithe-
lium to hyperplasia, atypical hyperplasia, in situ carcinoma
and invasive carcinoma (P = 0.016, P = 0.043, P = 0.005,
P = 0.0007, respectively), and decreased (not significant)
from hyperplasia to atypical hyperplasia and from hyperpla-
sia to in situ carcinoma (P = 0.08 and P = 0.064, respec-
tively). The P/A index increased significantly (P = 0.046)
from in situ carcinoma to invasive carcinoma. When atypi-
cal hyperplasia and in situ carcinoma were included in one
group (preinvasive lesions), the P/A index decreased (not
significant) from hyperplasia to preinvasive lesions
(P = 0.44) and increased significantly from preinvasive
lesions to invasive carcinoma (P = 0.041; Fig. 4).
Correlation between apoptotic and proliferative indices
A strong positive correlation between AI and PI was found
when all cases were taken into consideration by Spear-
man’s test (r = 0.83;  P < 0.001). When each group of
lesions was analyzed separately, Spearman’s correlation
demonstrated that AIs and PIs remained directly corre-
lated in the groups of typical hyperplasia (r = 0.45;
P = 0.041), preinvasive lesions (r = 0.7;  P = 0.001) and
invasive carcinoma (r = 0.26; P = 0.046). The correlation
index was not reliable in the normal epithelium group,
because of many zero values.
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Figure 1
Apoptotic cells in (a) ductal hyperplasia and (b, c) invasive ductal
nonspecific-type carcinomas detected using the TUNEL method. 
(a, b) Antidigoxigenin-peroxidase and (c) antidigoxigenin-FITC
visualization; 400× each. 
Figure 2
Ki-67 immunostaining in ductal invasive breast carcinomas. (a) Positive
neoplastic cells and (b) negative neoplastic cells, satisfying
morphological criteria of apoptosis. (c) Positive and negative apoptotic
body in the same field satisfying morphological criteria of apoptosis
Avidin-Biotin-Peroxidase complex; 1000× each. 
Table 1
The AIs and PIs per histological breast lesion
Tissue type n AI (%) PI (%)
Normal epithelium 32 0.00 (0.00–0.40) 0.10 (0.0–3.0)
Hyperplasia 43 0.02 (0.00–0.50) 1.22 (0.0–5.5)
Atypical hyperplasia 17 0.16 (0.08–0.84) 2.02 (1.8–9.3)
Carcinoma in situ 25 0.52 (0.13–2.06) 6.65 (1.3–24.0)
Carcinoma invasive 50 1.17 (0.16–3.69) 17.00 (1.0–50.0)
Total 167 0.21 (0.00–3.69) 2.26 (0.0–50.0)
Values are expressed as median (range).
(a) (c) (b) (a) (c) (b)Discussion
Accumulating evidence suggests that breast cancer arises
through a series of epithelial changes that range from
hyperplasia with and without atypia, followed by in situ
carcinoma to invasive carcinoma [6–9], although de novo
breast carcinogenesis cannot be ruled out. The in vivo
role of cell kinetics in the pathogenesis of breast cancer is
still unclear. To the best of our knowledge the present
study is the first to investigate apoptotic activity, prolifera-
tive activity and the balance between them in the spec-
trum of ductal epithelial lesions in breasts in which
preinvasive lesions and/or invasive carcinomas developed.
More than one lesion per case were evaluated. Each
lesion was studied in a different tissue area to avoid the
paracrine effect because both apoptosis and cell prolifera-
tion are active processes influenced by a wide variety of
intracellular and extracellular regulatory stimuli [1,2].
We found that an increase in the apoptotic and prolifera-
tive activity occurs in parallel with progression of epithelial
lesions. This provides further evidence for the continuum
in the pathogenetic process that leads to invasive ductal
Breast Cancer Research    Vol 3 No 4 Bai et al
Figure 3
Box and whisker plot depicting the median values, interquartile range and full range of (a) AIs and (b) PIs in normal epithelium, hyperplasia, atypical
hyperplasia, in situ carcinoma and invasive carcinoma.
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Table 2
The P/A index per histological breast lesion
Tissue type n P/A index
Normal epithelium 32 1.71 (0.00–46.00)
Hyperplasia 43 20.72 (0.74–48.67)
Preinvasive lesions 42 14.11 (3.67–58.00)
Carcinoma invasive 50 20.86 (3.87–301.00)
Total 167 16.66 (0.00–301.00)
Values are expressed as median (range).
Figure 4
Interaction plot of AI, PI and P/A index in normal epithelium,
hyperplasia, preinvasive lesion and invasive carcinoma.
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normal epithelium hyperplasia preinvasive lesion invasive carcinoma
PI
PI
AI
PI/AIcarcinoma. A quantitative study of apoptosis and cell pro-
liferation on a static-cell population, such as tissue sec-
tions, provides little information on the actual rapidity of
cell replication and loss. However, the present findings of
increasing frequency of apoptosis and cell proliferation
suggest the existence of an accelerating cell turnover
along the multistep process of breast carcinogenesis,
which could facilitate genetic events and clonal expansion.
Although the cause of breast cancer is unclear, mammary
tumourigenesis is believed to proceed through accumula-
tion of specific genetic alterations.
The PIs found in the present study are comparable to those
obtained by previous reports using similar methods
[20,21]. The present results on the incidence of apoptosis
using in situ visualization are generally in agreement with a
previous study reported by Mustonen et al [22], who evalu-
ated this cellular event in the complete spectrum of epithe-
lial lesions using the same method. In our series, which
consisted of more hyperplastic and preinvasive lesions, the
results showed significant differences among apparently
normal epithelium, hyperplasia, preinvasive lesions and
invasive carcinoma. Expression of the antiapoptotic bcl-2
protein exists in normal ductal epithelium, and decreases
from normal epithelium to in situ carcinoma and from in situ
to invasive carcinoma [23]. The expression of this protein is
also related to the degree of differentiation of neoplastic
breast epithelium [13,14]. Interestingly, apoptotic activity
was found to increase with disease progression, from dys-
plasia to invasive carcinoma in bronchial epithelium [24],
and from normal mucosa through dysplasia to invasive car-
cinoma in oral mucosa [25].
In this study we also compared the rate of proliferation
with that of apoptosis, because the balance between
these two events and the consequences of an imbalance
are fundamental to our understanding of how hyperplasia
and neoplasia develop. Both diseases are characterized
by a distinct increase in the number of epithelial cells. The
incidence of both cellular events increases in parallel with
the progression of epithelial lesions. However, an interest-
ing point resulting from this study is that, in the transition
from normal epithelium to hyperplasia and from preinva-
sive lesions to invasive carcinoma, proliferative activity
increases more than does apoptotic activity, resulting in a
growth imbalance in favour of cell proliferation.
Two studies by Harn and coworkers [16,26] reported a
higher degree of apoptosis and lower proliferative activity
in intraductal than in invasive carcinomas. Those investiga-
tors suggested that the higher degree of apoptosis and
lower proliferative activity in in situ than in invasive carcino-
mas could result in a steady-state condition, in which net
growth of the tumour is rare. The discrepancy between
their results and ours, together with those of Mustonen et
al [22], is mainly due to the higher degree of apoptosis
found in in situ than in invasive carcinomas by Harn and
coworkers [16,26]. They used the same method, and
necrotic areas were excluded from counting, as in the
present study, because DNA fragmentation detected using
the TUNEL method is a nonspecific marker of apoptosis.
Degenerative nuclei, which may represent the final stage of
cell death, either programmed or accidental, are labelled
using the TUNEL method [27]. Bodis et al [28] and Gandhi
et al [29] reported that, in in situ ductal carcinomas, the
apoptotic activity correlated with lesions of high histologi-
cal grade. Clinical follow-up studies [30,31] showed that,
in in situ ductal carcinomas, the high cytonuclear grade is
linked to a higher recurrence rate, and to a higher rate of
progression to invasive breast carcinomas. In the present
study, approximately half of the in situ carcinoma cases
progressed to invasive carcinomas, but the number of
cases was too small for a reliable statistical analysis.
The proliferative and apoptotic activities were similar in
atypical hyperplasia and in situ carcinoma, and the ratio
of proliferation to apoptosis decreased (non-significantly)
from hyperplasia to atypical hyperplasia or to in situ carci-
noma, indicating that the two lesions are kinetically
similar. Molecular genetic investigations demonstrated
that atypical ductal hyperplasia is a monoclonal rather
than a polyclonal epithelial proliferative lesion, and it has
been proposed that this lesion should be included within
the spectrum of in situ carcinoma [32,33]. The growth
imbalance in favour of apoptosis found in preinvasive
lesions is difficult to explain. Early genetic events are
already present in preinvasive breast lesions [32,33], and
apoptosis and growth arrest are responses to DNA
damage, although which of these events will occur in
each instance will depend on the extent of DNA damage,
cell type, location and environment. Apoptosis may be the
prudent option in damaged cells that retain substantial
replicative potential [4].
Furthermore, the present study demonstrated a strong
positive correlation between apoptotic and proliferative
activities. This finding is in accordance with previous
observations on the relationship between these two activi-
ties. Studies in in situ and invasive breast carcinomas
[34–36] showed positive correlation between apoptosis
and mitotic rate, S-phase fraction and Ki-67 immunoreac-
tivity. Similarly to invasive breast carcinomas, lymphomas,
ovarian carcinomas, and hepatocellular and laryngeal car-
cinomas showed a strong positive correlation between
these two cellular events [37–40]. Although apoptosis
and cell proliferation appear to be opposing and contra-
dictory processes, there is a recent substantial evidence
[4] that the two events may be related or coupled. Early
studies indicated that, under certain conditions, the
process of apoptosis is associated with abnormal expres-
sion of cell cycle regulatory proteins and activation of
cyclin-dependent kinases [41–43], suggesting that apop-
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htosis represents an abortive attempt by cells to pass
through the cell cycle.
In in situ and in invasive breast carcinomas, in which AIs
and PIs were higher, Ki-67-positive cells that satisfied
morphological criteria of apoptosis were observed in the
present study. Because the Ki-67 antigen is expressed
throughout the cell cycle [44], this observation indicates
that there were apoptotic cells among the proliferative
cells. There were also Ki-67-negative cells and apoptotic
bodies, even in the same case. We consider that a degra-
dation of the protein during the process of apoptosis or a
nonspecific uptake of the antibody by apoptotic cells is
unlikely. Therefore, these data indicate that apoptosis
does not always involve entry of cells into the cell cycle.
Carcinomatous breast cells can also undergo in vivo
apoptosis when they are in the resting G0 phase of the
cell cycle. A previous in vivo and in vitro study [45]
showed apoptotic bodies in lymphoid germinal centres
and in intestinal crypts to be often positive for Ki-67
antigen, whereas in polymorphonuclear leucocytes and in
premenstrual endometrium they were Ki-67 negative.
In conclusion, the results of this in vivo study indicate the
following: there is increasing cell turnover along the con-
tinuum from apparently normal epithelium through hyper-
plasia, to preinvasive lesions and invasive carcinoma;
atypical hyperplasia and in situ carcinoma may be kineti-
cally similar conditions; the net increase of cells in the
transition from normal epithelium to hyperplasia and from
preinvasive lesions to invasive carcinoma result from
growth imbalance in favour of cell proliferation; and in the
transition from hyperplasia to in situ carcinoma there is a
growth imbalance in favour of apoptosis.
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